Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Infectious Disease · Human Immunodeficiency Virus Infection

Undetectable Equals Untransmittable (U=U)

At a Glance

U=U means a person with HIV who takes treatment and maintains a viral load below 200 copies/mL for at least six months does not transmit HIV through sex. It does not make breastfeeding or sharing injection equipment zero-risk and does not prevent other STIs or pregnancy.

One of the most significant breakthroughs in HIV research is the discovery that effective treatment doesn’t just protect your health—it also protects your partners. This is known as Undetectable = Untransmittable (U=U). It means that when the amount of HIV in your blood is so low that it cannot be detected by a standard test, you cannot pass the virus to others through sex [1][2].

The Science Behind U=U

The U=U message is not just a slogan; it is backed by years of rigorous clinical research involving thousands of couples.

Major studies, including the PARTNER and PARTNER2 trials, followed couples where one partner was living with HIV and the other was not [3]. These couples engaged in tens of thousands of acts of condomless sex. The results were definitive: when the partner with HIV was on Antiretroviral Therapy (ART) and had an undetectable viral load, there were zero genetically linked transmissions of HIV to the HIV-negative partner [4][3].

The “6-Month Rule” and Thresholds

To ensure that U=U applies to you, doctors look for two key factors:

  1. A Low Viral Load (<200 copies/mL): In the United States and many international guidelines, the evidence-based threshold for U=U is a viral load of less than 200 copies/mL [5][2]. (Note: Your lab report might say “undetectable” below 20 or 50 copies/mL depending on the machine, but the clinical safety threshold for U=U is <200 copies/mL.)
  2. Sustained Suppression: U=U is most reliable after you have maintained a suppressed viral load for at least six months [2][4]. This timeline helps establish that your suppression is stable and reliable.

An isolated low-level blip below 200 usually does not negate U=U. However, a persistent rebound at or above 200 requires prompt clinical review, and the zero-risk message does not cover it.

Where U=U Does Not Apply

While U=U is a revolution for sexual health, the science is more complex for other types of exposure. In these cases, ART significantly reduces risk, but it is not currently considered “zero.”

  • Breastfeeding and Chestfeeding: HIV can be found in breast milk even when it is undetectable in the blood [6][7]. While the risk of transmission is very low when the viral load is suppressed, it is not zero, and rare cases of transmission have occurred [8][9]. Using formula or pasteurized donor milk completely eliminates breast-milk transmission. For this reason, healthcare providers use “shared decision-making” to help parents weigh the benefits against this small risk and provide strict monitoring [10].
  • Sharing Injection Equipment: While a low viral load likely reduces the risk of transmission through shared needles or syringes, there is not enough evidence to say the risk is zero [11]. Standard harm reduction—such as using sterile equipment through Syringe Service Programs (SSPs), accessing substance-use treatment, and PrEP for HIV-negative partners—remains the recommended way to prevent transmission in this context [12].

Total Sexual Health

U=U only applies to HIV. It does not prevent other sexually transmitted infections (STIs), such as syphilis, gonorrhea, or chlamydia, nor does it prevent pregnancy [1].

Even when you are undetectable, condoms remain a valuable tool for:

  • Preventing STIs that ART cannot treat.
  • Providing an extra layer of protection if you miss doses of your medication.
  • Preventing unintended pregnancy.

By staying on your treatment and keeping your viral load suppressed, you can enjoy a healthy sex life with the confidence that you are protecting your partners from HIV [13][14].

Common questions in this guide

What does HIV U=U mean?
U=U means that a person with HIV who takes antiretroviral therapy and maintains a viral load below 200 copies/mL does not transmit HIV through sex. The viral load is the amount of HIV in the blood, and it must remain suppressed with ongoing treatment and monitoring.
How long does my HIV viral load need to be suppressed for U=U?
U=U is most reliable after the viral load has stayed suppressed for at least six months. Your clinician can review your lab results and confirm whether your recent levels meet the less-than-200-copies/mL threshold.
Does an HIV viral-load blip mean I can transmit HIV?
A single low-level blip below 200 copies/mL usually does not end U=U. A persistent viral load at or above 200 copies/mL needs prompt clinical review because the zero-risk sexual-transmission message does not cover sustained rebound at that level.
Can I transmit HIV through breastfeeding or chestfeeding if I am undetectable?
Transmission is still possible, although the risk is very low, because HIV can be present in breast milk even when it is undetectable in the blood. Discuss feeding options and close monitoring with your healthcare team; formula or pasteurized donor milk eliminates breast-milk transmission.
Does U=U protect against HIV from shared needles?
No. Treatment likely lowers the chance of HIV transmission through shared injection equipment, but there is not enough evidence to call the risk zero. Using sterile equipment through a syringe service program and considering HIV-prevention medicine for HIV-negative partners are recommended prevention steps.
Do I still need condoms if my HIV is undetectable?
Condoms are not required to prevent sexual HIV transmission when U=U criteria are met, but they can help prevent syphilis, gonorrhea, chlamydia, and other sexually transmitted infections and unintended pregnancy. They can also provide extra protection if medication doses are missed or the viral load changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I been 'undetectable' long enough (at least 6 months) for the U=U zero-risk status to apply to my sexual health?
  2. 2.What is my most recent viral load number, and how often will we check it to make sure I stay suppressed?
  3. 3.If my viral load ever 'blips' or goes slightly above undetectable, what does that mean for my risk of transmitting the virus?
  4. 4.Since U=U doesn't apply to other STIs, which infections should my partner and I still be screened for regularly?
  5. 5.If I am considering having a baby or breastfeeding in the future, how will my treatment plan and monitoring change to keep the risk as low as possible?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Role of viral suppression in HIV treatment and prevention and its potential in addressing harmful laws and discrimination.

    Seale A, Baggaley R, Vojnov L, Doherty M

    Sexual health 2023; (20(3)):181-185 doi:10.1071/SH23048.

    PMID: 37407497
  2. 2

    Risk of sexual transmission of HIV in the context of viral load suppression.

    Djiadeu P, Begum H, Sabourin S, et al.

    Canada communicable disease report = Releve des maladies transmissibles au Canada 2023; (49(11-12)):457-464 doi:10.14745/ccdr.v49i1112a01.

    PMID: 38504878
  3. 3

    Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

    Rodger AJ, Cambiano V, Bruun T, et al.

    Lancet (London, England) 2019; (393(10189)):2428-2438 doi:10.1016/S0140-6736(19)30418-0.

    PMID: 31056293
  4. 4

    Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review.

    LeMessurier J, Traversy G, Varsaneux O, et al.

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2018; (190(46)):E1350-E1360 doi:10.1503/cmaj.180311.

    PMID: 30455270
  5. 5

    International guidelines for the management of healthcare workers living with HIV: a systematic comparative review.

    Diel R, Nienhaus A

    GMS hygiene and infection control 2026; (21()):Doc34 doi:10.3205/dgkh000643.

    PMID: 42038759
  6. 6

    Women living with HIV in high-income settings and breastfeeding.

    Moseholm E, Weis N

    Journal of internal medicine 2020; (287(1)):19-31 doi:10.1111/joim.12986.

    PMID: 31614046
  7. 7

    Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings.

    Waitt C, Low N, Van de Perre P, et al.

    The lancet. HIV 2018; (5(9)):e531-e536 doi:10.1016/S2352-3018(18)30098-5.

    PMID: 29960731
  8. 8

    Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis.

    Dugdale CM, Ufio O, Giardina J, et al.

    Lancet (London, England) 2025; (406(10501)):349-357 doi:10.1016/S0140-6736(25)00765-2.

    PMID: 40652949
  9. 9

    72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.

    Malaba TR, Nakatudde I, Kintu K, et al.

    The lancet. HIV 2022; (9(8)):e534-e543 doi:10.1016/S2352-3018(22)00173-4.

    PMID: 35905752
  10. 10

    2023 updated guidelines on infant feeding and HIV in the United States: what are they and why have recommendations changed.

    Pollock L, Levison J

    Topics in antiviral medicine 2023; (31(5)):576-586.

    PMID: 38198669
  11. 11

    Injection Practices and Sexual Behaviors Among Persons with Diagnosed HIV Infection Who Inject Drugs - United States, 2015-2017.

    Dasgupta S, Tie Y, Lemons A, et al.

    MMWR. Morbidity and mortality weekly report 2019; (68(30)):653-657 doi:10.15585/mmwr.mm6830a1.

    PMID: 31369525
  12. 12

    Human Immunodeficiency Virus Prevention for People Who Use Drugs: Overview of Reviews and the ICOS of PICOS.

    Johnson WD, Rivadeneira N, Adegbite AH, et al.

    The Journal of infectious diseases 2020; (222(Suppl 5)):S278-S300 doi:10.1093/infdis/jiaa008.

    PMID: 32877540
  13. 13

    The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.

    Broyles LN, Luo R, Boeras D, Vojnov L

    Lancet (London, England) 2023; (402(10400)):464-471 doi:10.1016/S0140-6736(23)00877-2.

    PMID: 37490935
  14. 14

    Rapid initiation of antiretroviral therapy for people living with HIV.

    Mateo-Urdiales A, Johnson S, Smith R, et al.

    The Cochrane database of systematic reviews 2019; (6()):CD012962 doi:10.1002/14651858.CD012962.pub2.

    PMID: 31206168

This page is for informational purposes only and does not constitute medical advice. Your HIV clinician should interpret your viral-load results and guide decisions about sex, breastfeeding or chestfeeding, and injection safety.

Get notified when new evidence is published on HIV infectious disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.